Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

Abraham Fisher, Rachel Brandeis, Rachel Haring, Naomi Eshhar, Eliahu Heldman, Yishai Karton, Orli Eisenberg, Haim Meshulam, Daniele Marciano, Nira Bar-Ner, Zipora Pittel

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.

Original languageEnglish
Pages (from-to)337-340
Number of pages4
JournalJournal of Physiology Paris
Volume92
Issue number5-6
DOIs
StatePublished - 1 Jan 1998
Externally publishedYes

Keywords

  • AF series
  • Alzheimer's disease
  • M1 agonists

ASJC Scopus subject areas

  • General Neuroscience
  • Physiology (medical)

Fingerprint

Dive into the research topics of 'Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis'. Together they form a unique fingerprint.

Cite this